Skeletal muscle atrophy
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Spastic tetraparesis
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Cerebellar atrophy
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Delayed myelination
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Protruding ear
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Sloping forehead
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Generalized hypotonia
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Progressive flexion contractures
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Profound global developmental delay
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Abnormality of brain morphology
|
0.100 |
GeneticVariation
|
phenotype |
CLINVAR |
|
|
|
Cerebral cortical atrophy
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Drosophila prune protein (h-prune) has been proved to play an essential role in regulating tumor metastasis.
|
30665854 |
2019 |
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Human PRUNE is thought to enhance the metastasis of tumor cells.
|
21234814 |
2011 |
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
The h-prune gene is involved in cellular motility and metastasis formation in breast cancer through interacting with the nm23-H1 protein.
|
15671547 |
2005 |
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
For the more aggressive sarcoma subtypes, 9/13 patients with PRUNE amplification developed metastases.
|
11687967 |
2001 |
Tumor Progression
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
We outline here the clinical importance of targeting of the Nme-1 (NDPK-A)-Prune-1 protein complex in cancer, where an imbalance in the formation of this protein-protein complex can result in inhibition of tumor progression.
|
29449633 |
2018 |
Tumor Progression
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
PRUNE is a member of the DHH (Asp-His-His) phosphoesterase protein superfamily of molecules important for cell motility, and implicated in cancer progression.
|
28334956 |
2017 |
Tumor Progression
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
This series of events suggests that the Nm23-H1/h-Prune protein complex regulates cancer progression and that its specific impairment could be a new therapeutic strategy in oncology.
|
25138575 |
2015 |
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
The identification of these two modes of inhibition of formation of the nm23-H1-h-prune protein complex pave the way toward new challenges, including translational studies using IC261 or this competitive peptide 'in vivo' to inhibit cellular motility induced by nm23-H1-h-prune complex formation during progression of breast cancer.
|
17906697 |
2008 |
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
The h-prune gene is involved in cellular motility and metastasis formation in breast cancer through interacting with the nm23-H1 protein.
|
15671547 |
2005 |
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
A similar situation was observed in all breast carcinomas with amplification of PRUNE.
|
11687967 |
2001 |
Congenital anomaly of brain
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Autosomal recessive PRUNE1 mutations are reported to cause a severe neurodevelopmental disorder with microcephaly, hypotonia, and brain malformations.
|
30556349 |
2019 |
Neurodegenerative Disorders
|
0.020 |
GeneticVariation
|
group |
BEFREE |
A homozygous canonical splice acceptor site mutation in PRUNE1 is responsible for a rare childhood neurodegenerative disease in Manitoba Cree families.
|
30556349 |
2019 |
Secondary Neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
Drosophila prune protein (h-prune) has been proved to play an essential role in regulating tumor metastasis.
|
30665854 |
2019 |
Neurodegenerative Disorders
|
0.020 |
GeneticVariation
|
group |
BEFREE |
This novel feature expands the clinical consequences of PRUNE mutations and allow to converge PRUNE syndrome with previous descriptions of neurodevelopmental/neurodegenerative disorders linked to altered microtubule dynamics.
|
29307700 |
2018 |